-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
-
Summary
-
Verve Therapeutics, Inc. quarterly/annual Depreciation history and growth rate from Q2 2020 to Q2 2024.
- Verve Therapeutics, Inc. Depreciation for the quarter ending June 30, 2024 was $1.67M, a 24.7% increase year-over-year.
- Verve Therapeutics, Inc. Depreciation for the twelve months ending June 30, 2024 was $6.29M, a 53.2% increase year-over-year.
- Verve Therapeutics, Inc. annual Depreciation for 2023 was $5.46M, a 94.5% increase from 2022.
- Verve Therapeutics, Inc. annual Depreciation for 2022 was $2.8M, a 82.7% increase from 2021.
- Verve Therapeutics, Inc. annual Depreciation for 2021 was $1.54M, a 15.6% increase from 2020.
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Growth (%)